» Articles » PMID: 33706618

Development and Validation of Novel Nomograms for Predicting Specific Distant Metastatic Sites and Overall Survival of Patients With Soft Tissue Sarcoma

Overview
Date 2021 Mar 12
PMID 33706618
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The goal of this study is to construct nomograms to effectively predict the distant metastatic sites and overall survival (OS) of soft tissue sarcoma (STS) patients.

Methods: STS case data between 2010 and 2015 for retrospective study were gathered from public databases. According to the chi-square and multivariate logistic regression analysis determined independent predictive factors of specific metastatic sites, the nomograms based on these factors were consturced. Subsequently, combined metastatic information a nomogram to predict 1-, 2-, and 3-year OS of STS patients was developed. The performance of models was validated by the area under the curve (AUC), calibration plots, and decision curve analyses (DCA).

Results: A total of 7001 STS patients were included in this retrospective study, including 4901 cases in the training group and the remaining 2,100 patients in the validation group. Three nomograms were established to predict lung, liver and bone metastasis, and satisfactory results have been obtained by internal and external validation. The AUCs for predicting lung, liver, and bone metastases in the training cohort were 0.796, 0.799, and 0.766, respectively, and in the validation cohort were 0.807, 0.787, and 0.775, respectively, which means that the nomograms have good discrimination. The calibration curves showed that the models have high precision, and the DCA manifested that the nomograms have great clinical application prospects. Through univariate and multivariate COX regression analyses, 8 independent prognosis factors of age, grade, histological type, tumor size, surgery, chemotherapy, radiatiotherapy and lung metastasis were determined. A nomogram was then constructed to predict the 1-, 2-, and 3-years OS, which has a good performance in both internal and external validations.

Conclusion: The nomograms for predicting specific metastatic sites and OS have good discrimination, accuracy and clinical applicability. The models could accurately predict the metastatic risk and survival information, and help clinical decision-making.

Citing Articles

Prognostic Role of OX40, LAG-3, TIM-3 and PD-L1 Expression in Bone and Soft Tissue Sarcomas.

Kurt Inci B, Acar E, Gurler F, Ilhan A, Yildiz F, Ardic F J Clin Med. 2024; 13(12).

PMID: 38930150 PMC: 11204964. DOI: 10.3390/jcm13123620.


A Mixed-Methods Study to Better Measure Patient-Reported Pain and Fatigue in Soft Tissue Sarcoma.

Barrett L, Elliott E, Voorhaar M, Ingelgard A, Griebsch I, Wong B Oncol Ther. 2023; 11(1):129-143.

PMID: 36633810 PMC: 9935765. DOI: 10.1007/s40487-022-00219-y.


Nomograms predicting local and distant recurrence and disease-specific mortality for R0/R1 soft tissue sarcomas of the extremities.

De Sanctis R, Zelic R, Santoro A Front Oncol. 2022; 12:941896.

PMID: 36203418 PMC: 9530899. DOI: 10.3389/fonc.2022.941896.


Prediction tools for the personalized management of soft-tissue sarcomas of the extremity.

Acem I, van de Sande M Bone Joint J. 2022; 104-B(9):1011-1016.

PMID: 36047022 PMC: 9987162. DOI: 10.1302/0301-620X.104B9.BJJ-2022-0647.


Impact of Smoking History on Pulmonary Metastasis-free Survival in Patients With Soft-tissue Sarcoma.

Matsuoka M, Okamoto M, Soma T, Yokota I, Arai R, Onodera T Cancer Diagn Progn. 2022; 1(2):89-94.

PMID: 35403129 PMC: 8962765. DOI: 10.21873/cdp.10013.

References
1.
Gronchi A, Miceli R, Shurell E, Eilber F, Eilber F, Anaya D . Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 2013; 31(13):1649-55. DOI: 10.1200/JCO.2012.44.3747. View

2.
Tseng W, Pasquali S, Hu J, Menendez L, Gronchi A . Staging systems and nomograms in soft tissue sarcoma: outcome prediction by categorization or personalization?. Chin Clin Oncol. 2019; 8(S1):S12. DOI: 10.21037/cco.2019.01.05. View

3.
Van Glabbeke M, Van Oosterom A, Oosterhuis J, Mouridsen H, Crowther D, Somers R . Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and.... J Clin Oncol. 1999; 17(1):150-7. DOI: 10.1200/JCO.1999.17.1.150. View

4.
Italiano A, Mathoulin-Pelissier S, Cesne A, Terrier P, Bonvalot S, Collin F . Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2010; 117(5):1049-54. DOI: 10.1002/cncr.25538. View

5.
Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A . Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001; 19(5):1238-47. DOI: 10.1200/JCO.2001.19.5.1238. View